Currently, the most promising cell cycle inhibitors in anticancer therapeutics are orally bioavailable CDK4/6 inhibitors, which have received regulatory approval in combination with hormonal therapy for treatment of patients with metastatic hormone receptor (HR)-positive, Her2-negative breast cancer [25,26,27,28,29]. The gene discussed is HR; the disease is breast cancer.